FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W109216922> ?p ?o ?g. }

• W109216922 endingPage "VRT.S631" @default.
• W109216922 startingPage "VRT.S631" @default.
• W109216922 abstract "Kaposi’s sarcoma (KS) was originally described in 1872 by the Hungarian dermatologist Moritz Kaposi as an idiopathic, multiple pigmented sarcoma of the skin. This type of KS, later classifi ed as classic KS, predominantly occurred in elderly people, particularly men of Mediterranean, Eastern European, or Jewish descent. A high occurrence of African or endemic KS was reported during the early 1950’s in equatorial African countries, while during the 1960’s KS emerged among immune-suppressed patients following organ transplantation. A tremendous increase in the incidence of KS was noticed during the early 1980’s in parallel with the acquired immunodefi ciency syndrome (AIDS) epidemic, leading to a formal recognition of KS as an AIDS-associated malignancy. The geographic variations in the incidence of KS together with the relatively high occurrence of AIDS-KS, particularly among homosexual men, suggested the existence of a unique KS infectious agent (7, 8). In 1994 Chang and colleagues, amplifi ed two novel DNA sequences from an AIDS-associated KS lesion, by using a subtractive hybridization technique (representational difference analysis (RDA)). These sequences displayed homology to herpesviral capsid and tegument genes and led to the complete sequencing of the 165 Kbp viral genome of the newly discovered virus, Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) or human herpesvirus 8 (HHV-8). KSHV was established as being present in virtually all pathologically confi rmed KS specimens (11, 12). Treatment with highly active antiretroviral therapy (HAART) has been associated with a dramatic decline in the incidence of KS (31), so that AIDS-associated KS is uncommon overall in the Western world. Sub-Saharan Africa has the highest rates of infection (due mostly to the high rates of AIDS) with many countries experiencing sera-prevalence rates exceeding 60%, so that in certain African countries it is now the most common cancer in adult men, and the second most common in adult women (44). The incidence of KS among transplant recipients is proportional to the ethno-geographical prevalence of KSHV, ranging from 0.5% in most Western countries to 5.3% in Saudi Arabia (50). In addition to KS, which is a tumour of endothelial cell origin, several haematological predominantly B cell disorders are also associated with KSHV. The two most well characterized are AIDS-associated primary effusion lymphomas (PEL) and a subset of multicentric Castleman’s disease (MCD), an aggressive lymphoproliferative disorder. PELs are monoclonal, non-Hodgkin’s B cell lymphomas that are commonly co-infected with EBV. Cell lines established from PEL, unlike KS tumour explants, stably maintain viral episomes at high copy number (30–150 copies per cell) and are the source of virus for most virologic and serologic studies. Most studies on latency of gammaherpesviruses (EBV) used lymphoblastoid cell lines that were derived from lymphomas or were established by in vitro infection/immortalization of peripheral blood lymphocytes. In vitro immortalized cells lines can be cultured indefi nitely. PEL cell lines that carry latent KSHV have been successfully established, although no in vitro immortalization of B lymphocytes has been reported yet (10, 44). KSHV viral genome consists of a ∼140kb long unique coding region fl anked by a multiple GC rich ∼800bp TRs (terminal repeats) giving a total estimated size of around 170kb (57, 60). In analogy" @default.
• W109216922 created "2016-06-24" @default.
• W109216922 creator A5055278348 @default.
• W109216922 creator A5074484305 @default.
• W109216922 creator A5074633349 @default.
• W109216922 date "2008-01-01" @default.
• W109216922 modified "2023-10-18" @default.
• W109216922 title "KSHV Latency in Transformed B-cells: The Role of LANA1 as a Therapeutic Target" @default.
• W109216922 cites W1491026704 @default.
• W109216922 cites W1566845420 @default.
• W109216922 cites W1604210388 @default.
• W109216922 cites W1673837423 @default.
• W109216922 cites W17705042 @default.
• W109216922 cites W1861124997 @default.
• W109216922 cites W1965641444 @default.
• W109216922 cites W1972008542 @default.
• W109216922 cites W1974538337 @default.
• W109216922 cites W1986723482 @default.
• W109216922 cites W1990386824 @default.
• W109216922 cites W1991952124 @default.
• W109216922 cites W1993825828 @default.
• W109216922 cites W1994072014 @default.
• W109216922 cites W1995912453 @default.
• W109216922 cites W2006224384 @default.
• W109216922 cites W2008724789 @default.
• W109216922 cites W2013739925 @default.
• W109216922 cites W2018091905 @default.
• W109216922 cites W2018138792 @default.
• W109216922 cites W2020458592 @default.
• W109216922 cites W2021522625 @default.
• W109216922 cites W2028318125 @default.
• W109216922 cites W2028613979 @default.
• W109216922 cites W2032438721 @default.
• W109216922 cites W2035092384 @default.
• W109216922 cites W2041158839 @default.
• W109216922 cites W2047399907 @default.
• W109216922 cites W2066158249 @default.
• W109216922 cites W2066410692 @default.
• W109216922 cites W2070204121 @default.
• W109216922 cites W2070335382 @default.
• W109216922 cites W2073848242 @default.
• W109216922 cites W2081651119 @default.
• W109216922 cites W2082281799 @default.
• W109216922 cites W2084473128 @default.
• W109216922 cites W2085622884 @default.
• W109216922 cites W2086928977 @default.
• W109216922 cites W2089204594 @default.
• W109216922 cites W2089470376 @default.
• W109216922 cites W2091197267 @default.
• W109216922 cites W2094584112 @default.
• W109216922 cites W2097493532 @default.
• W109216922 cites W2104173161 @default.
• W109216922 cites W2110599787 @default.
• W109216922 cites W2114205900 @default.
• W109216922 cites W2114735542 @default.
• W109216922 cites W2117373553 @default.
• W109216922 cites W2117945149 @default.
• W109216922 cites W2123422243 @default.
• W109216922 cites W2131715177 @default.
• W109216922 cites W2132014894 @default.
• W109216922 cites W2132982759 @default.
• W109216922 cites W2134447274 @default.
• W109216922 cites W2142107992 @default.
• W109216922 cites W2143090686 @default.
• W109216922 cites W2146428402 @default.
• W109216922 cites W2146947146 @default.
• W109216922 cites W2149144186 @default.
• W109216922 cites W2149489978 @default.
• W109216922 cites W2155587524 @default.
• W109216922 cites W2159163386 @default.
• W109216922 cites W2159265435 @default.
• W109216922 cites W2161637195 @default.
• W109216922 cites W2168492746 @default.
• W109216922 cites W2169661325 @default.
• W109216922 cites W2314609747 @default.
• W109216922 cites W2410723119 @default.
• W109216922 cites W4236064436 @default.
• W109216922 doi "https://doi.org/10.4137/vrt.s631" @default.
• W109216922 hasPublicationYear "2008" @default.
• W109216922 type Work @default.
• W109216922 sameAs 109216922 @default.
• W109216922 citedByCount "1" @default.
• W109216922 countsByYear W1092169222021 @default.
• W109216922 crossrefType "journal-article" @default.
• W109216922 hasAuthorship W109216922A5055278348 @default.
• W109216922 hasAuthorship W109216922A5074484305 @default.
• W109216922 hasAuthorship W109216922A5074633349 @default.
• W109216922 hasBestOaLocation W1092169221 @default.
• W109216922 hasConcept C159047783 @default.
• W109216922 hasConcept C41008148 @default.
• W109216922 hasConcept C502942594 @default.
• W109216922 hasConcept C76155785 @default.
• W109216922 hasConcept C82876162 @default.
• W109216922 hasConcept C86803240 @default.
• W109216922 hasConcept C95444343 @default.
• W109216922 hasConceptScore W109216922C159047783 @default.
• W109216922 hasConceptScore W109216922C41008148 @default.
• W109216922 hasConceptScore W109216922C502942594 @default.

• next